Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19006345 | 0.82 | TSHR (0.34) | TSHRMAPK1L3MBTL1NPC1ALDH1A1 | |
| SCHEMBL18999238 | 0.81 | HRH4 (0.37) | TSHRMAPK1L3MBTL1HDAC1CYP2C19 | |
| SCHEMBL19006404 | 0.80 | TSHR (0.38) | TSHRMAPK1L3MBTL1NPC1CYP1A2 | |
| SCHEMBL12196326 | 0.76 | GGPS1 (0.39) | GGPS1L3MBTL1 | |
| SCHEMBL8976563 | 0.75 | MAPK1 (0.39) | TSHRMAPK1HDAC1NPC1KMT2A | |
| SCHEMBL18136576 | 0.75 | ALOX5 (0.35) | GGPS1ALOX5 | |
| SCHEMBL18377722 | 0.75 | NPC1 (0.46) | GGPS1MAPK1HDAC1NPC1ALOX5 | |
| SCHEMBL19708375 | 0.73 | GGPS1 (0.34) | GGPS1ALOX5 | |
| SCHEMBL20915722 | 0.72 | NR1H4 (0.34) | GGPS1TSHRMAPK1L3MBTL1HDAC1 | |
| SCHEMBL19006343 | 0.72 | ALDH1A1 (0.38) | TSHRMAPK1NPC1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | GGPS1 202/4885TSHR 379/4885MAPK1 1148/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | GGPS1 202/4885TSHR 379/4885MAPK1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.